Nitrogen removal performance in roadside stormwater bioretention cells amended with drinking water treatment residuals.

Bioretention cells, a type of green stormwater infrastructure, have been shown to reduce runoff volumes and remove a variety of pollutants. The ability of bioretention cells to remove nitrogen and phosphorus, however, is variable, and bioretention soil media can act as a net exporter of nutrients. This is concerning as excess loading of nitrogen and phosphorus can lead to eutrophication of surface waters, which green stormwater infrastructure is intended to ameliorate.

Phosphorus removal, metals dynamics, and hydraulics in stormwater bioretention systems amended with drinking water treatment residuals.

Drinking water treatment residuals (DWTRs) are a promising media amendment for enhancing phosphorus (P) removal in bioretention systems, but substantial removal of dissolved P by DWTRs has not been demonstrated in field bioretention experiments. We investigated the capacity of a non-amended control media (Control) and a DWTR-amended treatment media (DWTR) to remove soluble reactive P (SRP), dissolved organic P (DOP), particulate P (PP), and total P (TP) from stormwater in a two-year roadside bioretention experiment. Significant reductions m SRP, PP and TP concentrations and loads were observed in both the Control and DWTR media.

Balancing Hydraulic Control and Phosphorus Removal in Bioretention Media Amended with Drinking Water Treatment Residuals.

Green stormwater infrastructure like bioretention can reduce stormwater runoff volumes and trap sediments and pollutants. However, bioretention soil media can be both a sink and source of phosphorus (P). We investigated the potential tradeoff between hydraulic conductivity and P sorption capacity in drinking water treatment residuals (DWTRs), with implications for bioretention media design.

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.

Background: Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-related peptide, has demonstrated a significant reduction in monthly migraine headache days compared with placebo. Here, we analyze data from 3 randomized clinical trials (2 episodic trials [EVOLVE-1, EVOLVE-2] and 1 chronic trial [REGAIN]), to examine if galcanezumab also alleviates the severity and symptoms of migraine.

Methods: The episodic migraine trials were 6-month, double-blind studies in patients with episodic migraine (4-14 monthly migraine headache days).